Related Experiment Videos

Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study

K A Forde1, K Haynes, A B Troxel

  • 1Division of Gastroenterology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. kimberly.forde@uphs.upenn.edu

Insights

Hepatitis C virus (HCV) infection does not increase the risk of acute myocardial infarction (MI). This study found no significant difference in MI incidence between HCV-infected and uninfected individuals, suggesting HCV is not an independent risk factor for heart attack.

Area of Science:

  • Hepatology
  • Cardiology
  • Epidemiology

Background:

  • Hepatitis C virus (HCV) infection is linked to systemic inflammation and metabolic issues, potentially increasing atherosclerosis risk.
  • The association between HCV infection and acute myocardial infarction (MI) risk remains unclear.

Purpose of the Study:

  • To investigate if HCV infection is an independent risk factor for incident acute MI in adults.
  • To determine the relationship between HCV diagnosis and cardiovascular events in a UK general practice setting.

Main Methods:

  • A retrospective cohort study using The Health Improvement Network (THIN) database (1996-2008).
  • Matched cohort design: 4809 HCV-infected patients matched with 71,668 HCV-uninfected patients.
  • Cox proportional hazards regression was used to estimate adjusted hazard ratios, controlling for cardiovascular risk factors.

Main Results:

  • No significant difference in MI incidence rates between HCV-infected and uninfected patients (1.02 vs 0.92 events per 1000 person-years).
  • HCV infection was not associated with an increased risk of incident MI (adjusted HR, 1.10; 95% CI, 0.67-1.83).
  • Sensitivity analyses, including composite outcomes, also showed no increased risk.

Conclusions:

  • HCV infection is not associated with an increased risk of incident acute myocardial infarction.
  • The findings suggest that HCV is not an independent risk factor for MI in the general adult population.
  • Further research may explore specific subgroups or mechanisms if needed.

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...